Kelun Botai
Latest round
- Series B
Last raised
- Dec 2022
Total raised
- $193M
Investors
- 10
About Kelun Botai
Established in 2016 and based in Chengdu, China, Kelun Botai is a biopharmaceutical company that focuses on the research and development, production, and sales of molecular biology medical drugs., Ltd. In 2022, it established cooperation with Merck Sharp & Dohme LLC, got 9 authorized drugs cooperation, and the total amount reached USD 11 billion. In July 2023, it was listed on the Hongkong Stock Exchange with stock code 6990. The Chairman of the Board, Gexin Liu, graduated from Dalian University and he served as a director of Kelun Research Institute from November 2020 to October 2022. The company's business is the research and development, production, and distribution of small molecular drugs. It used the technologies of antibody-drug conjugates (ADC), bispecific monoclonal antibodies (BMA), and new targets. It has 33 drug programs, used for the treatment of tumors, inflammation, and metabolic diseases such as breast cancer, stomach cancer, lung cancer, etc. It includes 14 drug programs in clinical trials in China, and 3 programs performed in clinical trials in the USA.039 million.
Who invested in Kelun Botai
10 investors across 1 round
See all investors in Kelun Botai
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Dec 29, 2022
Amount
$193M
Investors
Questions about Kelun Botai
Who invested in Kelun Botai?
Kelun Botai has 10 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kelun Botai raised?
Kelun Botai has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Kelun Botai last raise money?
Kelun Botai's most recent round on record is a Series B, in Dec 2022.
What does Kelun Botai do?
Established in 2016 and based in Chengdu, China, Kelun Botai is a biopharmaceutical company that focuses on the research and development, production, and sales of molecular biology medical drugs.
Where is Kelun Botai headquartered?
Kelun Botai is headquartered in Chengdu, China.
Which VCs invest in companies like Kelun Botai?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Kelun Botai's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Kelun Botai? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.